NCT03639935View on ClinicalTrials.gov

Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 28, 2019

Primary Completion Date

February 7, 2023

Study Completion Date

April 30, 2024

Conditions
Biliary Tract Cancer
Interventions
DRUG

Rucaparib

Rucaparib 600 mg PO BID days 1-28

DRUG

Nivolumab

Nivolumab 240 mg IV days 1 and 15

Trial Locations (3)

37232

Vanderbilt University Medical Center, Nashville

48109

Rogel Cancer Center, Ann Arbor

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Vanderbilt University Medical Center

OTHER

lead

University of Michigan Rogel Cancer Center

OTHER

NCT03639935 - Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy | Biotech Hunter | Biotech Hunter